This is one of those companies where the fundamentals match the chart. This company is bringing gene editing to cancer and biodevelopment. The leading diagonal is super promising to have a strong first wave that would finish at ATH. After the Fib correction this could fly outside the pitchfork and really show longterm growth. Price targets on the next two waves are given as well as an estimate pathway to break out of the diagonal